Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1
Sander F. Garrelfs(Emma Kinderziekenhuis), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Elisabeth L. Metry(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Henk Schierbeek(Emma Kinderziekenhuis), Chris H.P. van den Akker(Amsterdam University Medical Centers), Dewi van Harskamp(Emma Kinderziekenhuis), Frédéric M. Vaz(Netherlands Metabolomics Centre)
Cited by 13
Related Papers
Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies
|Nature Medicine|2014|843
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
Mutations in LPIN1 Cause Recurrent Acute Myoglobinuria in Childhood
|The American Journal of Human Genetics|2008|218
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154